DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the release of its second-quarter 2023 financial results on August 14th, followed by a live conference call on August 15th to discuss business updates. The company is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14^th. DiaMedica will host a live conference call on Tuesday, August 15^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:

Date:	Tuesday, August 15, 2023
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://app.webinar.net/DnqEQYkbk6Z
Dial In:	(877) 550-1858
Conference ID:	2125#

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 22, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230808344534/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics release its second-quarter 2023 financial results?

DiaMedica Therapeutics will release its second-quarter 2023 financial results after the markets close on Monday, August 14th.

What is DiaMedica's focus in terms of drug development?

DiaMedica is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.

When is the live conference call to discuss business updates and financial results?

The live conference call to discuss business updates and financial results will be held on Tuesday, August 15th at 7:00 AM Central Time.

How can interested parties access the conference call?

Interested parties can access the conference call by dialing in or listening to the simultaneous webcast. Web access and dial-in details are available on the company's website.